In this follow-up study presenting results at 96 weeks, cabotegravir and rilpivirine long-acting therapy remained noninferior to oral therapy, had acceptable safety and tolerability profiles, and resulted in durable virologic suppression, further supporting its consideration for African treatment programs.
- Cissy Kityo
- Ivan K. Mambule
- Veerle Van Eygen
